NDC 0409-2012-03 - Buprenorphine Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0409-2012
- Requested NDC
- 0409-2012-03
- Package NDCs from labels
- 0409-2012-03, 0409-2012-32
- Manufacturer
- Hospira, Inc. | Macfarlan Smith Limited
- Effective date
- 2025-12-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine Hydrochloride - Hospira, Inc. | Macfarlan Smith Limited | Hospira, Inc. | Macfarlan Smith Limited | 2025-12-31 | HUMAN PRESCRIPTION DRUG LABEL |
| Buprenorphine Hydrochloride - Rebel Distributors Corp | Rebel Distributors Corp | 2010-12-10 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0409-2012-03 | Buprenorphine Hydrochloride | 1 mL in 1 CARTRIDGE | INJECTION, SOLUTION | 1 | 20 | |
| 0409-2012-32 | Buprenorphine Hydrochloride | 10 in 1 CARTON | INJECTION, SOLUTION | 10 | 20 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0409-2012-03 | ML - Milliliter | 0409-2012 | cfea3dc4-46db-4825-9a09-f7b80f48554f | 1 | 2017-07-07 |
| 0409-2012-32 | ML - Milliliter | 0409-2012 | 9849ebbb-eecf-4f04-90c7-5bc540c548f9 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Golden State Medical Supply, Inc. | 4f6e0056-b19d-0d0e-e063-6294a90a16e5 | 2026-04-24 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 5005a6c8-9a3b-a99a-e063-6294a90aac13 | 2026-04-22 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 63aaa6cc-8574-4990-8239-6fdeffce92c8 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Unit Dose Solutions, Inc. | 4f979409-f9a2-d3a2-e063-6394a90accd0 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Aveva Drug Delivery Systems Inc. | cb112448-49a1-4209-bcdb-7cfae6501f51 | 2026-04-07 | Warnings, Adverse reactions | 56W8MW3EN1 |
| KIDS TOOTHPASTE, FOR CAVITY PROTECTION | KIDS TOOTHPASTE FOR CAVITY PROTECTION | Shulisa (Foshan) Daily ChemicalIndustry Co., Ltd | 4e8fab9e-f05c-5e2f-e063-6294a90aecf9 | 2026-04-03 | Warnings | 059QF0KO0R |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | cd0a90c6-32cc-4114-8573-86ac85503bdf | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 2aaad1a7-a0fd-4dd5-bb53-03afad8f10b9 | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | INGENUS PHARMACEUTICALS, LLC | 4951ec29-609b-4836-b0e4-0d9c1d6ae6fe | 2026-03-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl | BUPRENORPHINE HCL | REMEDYREPACK INC. | 69a647c0-bc09-4ee2-aeb3-ef286caf25e5 | 2026-03-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Sterile Water | WATER | Hospira, Inc. | 2b9ea23a-f9e9-48a8-25b7-519e3bbd6828 | 2026-03-18 | Warnings, Adverse reactions | 059QF0KO0R |
| TINTED SUNSCREEN FOUNDATION | TINTED SUNSCREEN FOUNDATION | Guanghzou AiXin Biotech Co Ltd | 396393c4-b50c-3877-e063-6294a90a0e9b | 2026-03-17 | Warnings | 059QF0KO0R |
| Skin Irritations and Itch Relief | AGARICUS MUSCARIUS, ALUMINA, ANAGALLIS ARVENSIS, ANTIMONIUM TARTARICUM, APIS MELLIFICA, ARSENICUM ALBUM, ARSENICUM IODATUM, BOVISTA, CAUSTICUM, DOLICHOS PRURIENS, FAGOPYRUM ESCULENTUM, GRAPHITES, KALI MURIATICUM, MURIATICUM ACIDUM, OLEANDER, PETROLEUM, PIX LIQUIDA, RADIUM BROMATUM (12X, 30X, 1LM), RHUS TOX, SELENIUM METALLICUM, SULPHUR AND URTICA URENS. | King Bio Inc. | d139d2f1-0369-4963-9f3d-c4cc0f1ea2dd | 2026-03-10 | Warnings | QTT17582CB |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 99a5b62f-bc08-44f4-abb8-300520d2162a | 2026-03-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| 2-Pack Facial Serum | 2-PACK FACIAL SERUM | Guangzhou Ariel Biotech Co., Ltd. | 27c7f645-cfb3-6db1-e063-6394a90a42ff | 2026-03-06 | Warnings | 059QF0KO0R |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 8f2b94dc-f42f-45d5-8274-9e748ec20ef0 | 2026-03-05 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Major Pharmaceuticals | c5fbec69-e7de-44a8-b9fa-0378ae61a9fe | 2026-03-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | 442831cf-9636-433a-9a12-e9a8cd31f72a | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 300ae3d0-464c-d0be-e063-6294a90a7f9d | 2026-02-21 | Warnings, Adverse reactions | 56W8MW3EN1 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.